Zachariah DeFilipp, MD, presents data from AGAVE-201, a phase 2, open-label, randomized, multicenter study evaluating axatilimab at 3 dose levels in patients with recurrent/refractory chronic graft-versus-host disease (GVHD).
Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC
Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer
Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist